KROMATID is a contract research organization (CRO) specializing in cytogenetic precision, empowering the cell and gene therapy community with advanced genomic integrity analysis solutions. Through our cutting-edge KROMASURE™ platform, we provide high-confidence, single-cell insights into chromosomal integrity, -filling critical gaps left by traditional sequencing methods. Our cytogenetic platform helps biotech, pharma, CDMOs, and academic researchers accelerate breakthroughs, ensure regulatory confidence, and drive innovation in genomic medicine. With a commitment to data-driven innovation, transparency, and continuous improvement, KROMATID is revolutionizing human medicine-seeing is believing. 


Industries
Biotechnology
Health Care & Hospitals
Medical Pharmaceuticals
Pharmaceuticals
Health

Contact Information
Amanda Ladas, Global Marketing Manager
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Aug 20, 2025, 14:04 ET KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a...

Jul 22, 2025, 10:16 ET KROMATID Works With Consortium to Empower Cancer Genomics with Industry-Leading Sequencing Standards

KROMATID proudly announces its pivotal role within a groundbreaking public–private–academic consortium - including the prestigious National Institute ...

May 27, 2025, 13:23 ET KROMATID Launches KROMASURE(TM) PinPoint: Next Generation, High-Throughput Transgene Integration Analysis

KROMATID, a leader in structural genomics innovation, is proud to announce the release of an expanded capability for its Advanced Cytogenetics...

Feb 06, 2024, 08:38 ET Stony Brook Study on the Role of DNA Amplification in Cancer Chemoresistance Leverages KromaTiD dGH in-Site™ Technology

A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause of drug resistance in...

Nov 30, 2023, 08:39 ET KromaTiD and SeQure Dx Enter Partnership Agreement to Offer Comprehensive, IND-Enabling Gene Editing Services Supporting Cell and Gene Therapy Research

KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell...

Jul 20, 2023, 08:36 ET KromaTiD Launches directional Genomic Hybridization (dGH) in-Site™ DNA Probes, Expanding Access for Cell and Gene Therapy Research Programs

KromaTiD, a single-cell analysis life science tools company focused on the research, development and commercialization of products for the cell and...

Mar 27, 2023, 10:40 ET KromaTiD Launches dGH in-Site™ CAR-T Kit for TRAC & B2M, Putting Single-Cell Gene Editing Analysis Tech in Customer Hands

KromaTiD, a single-cell analysis life science tools company focused on the research, development, and commercialization of technology solutions for...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.